Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer

This year, our intellectual property portfolio was significantly expanded and strengthened. This was achieved by filing four patent applications in the areas CAR T-cell therapies and mRNA vaccines. Science is moving forward. The Company has many promising products in its pipeline, but we must focus our limited resources on what we believe will be most beneficial to patients and shareholders. DuraCAR is a CAR-T-cell therapy that we are currently developing. This cell therapy will use our shRNA technology that targets the immune checkpoint, NR2F6 within a CAR-T-cell. This cell therapy should be able kill solid tumors, as well as lymphomas and leukemias. In the next months, we expect more results from our CRO partners. We are pleased to announce that Dr. Ravinder Reddy (University of Pennsylvania) and Dr. Mohammad Haris (University of Pennsylvania) have joined our Scientific Advisory Board. Concerning financing, our convertible debt decreased dramatically from $3,024,080 principal and $652 905 accrued interests as of March 31, 2022, to a current balance of $510,000 principal, and $250,859 accrued in interest in 2022. We will prioritize expanding our management team once we have raised enough funds. Last but not least, I would like to thank all our shareholders. Regen BioPharma, Inc., is a publicly traded biotechnology firm (PINK, RGBP) or (PINK, RGBPP). The Company's focus is on immunology and immunotherapy. The Company's goal is to rapidly advance novel technologies through preclinical and Phase I/I clinical trials. The Company's current focus is on small molecule and mRNA therapies to treat cancer and other autoimmune diseases. Forward-looking statements may be included in this news announcement. Forward-looking statements can be subject to uncertainties and risks. Some of these cannot be predicted or quantified. Future events and actual results may differ materially from the ones contained in, contemplated or underlying forward-looking statements. CONTACT INFORMATION

Regen BioPharma Inc.David R. Koos, Ph.D.Chairman & Chief Executive Officer+1-619-722-5505 Phone+1-619-330-2328 Fax